1258011-97-0
Chemical Structure
OLHHA
- CAS No.: 1258011-97-0
- Formula:C27H45NO3
- Molecular Weight:431.65
IUPAC Name: N-(1-(3,4-dihydroxyphenyl)propan-2-yl)oleamide
InChIKey: XIPFMGYXSZQUGV-KHPPLWFESA-N
SMILES: CCCCCCCC/C=C\CCCCCCCC(NC(C)CC1=CC=C(O)C(O)=C1)=O
Biological Activity: OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC50 value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
OLHHA | OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC50 value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Alen F, et al. PPARα/CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models. Biochem Pharmacol. 2018 Nov;157:235-243. [Content Brief]
- [2]. Decara JM, et al. Treatment with a novel oleic-acid-dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats. Dis Model Mech. 2015 Oct 1;8(10):1213-25. [Content Brief]
Keywords
